{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:27:31Z","timestamp":1787113651931,"version":"build-2736575974"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>We aimed to analyze the benign and malignant identification efficiency of CA125, HE4, risk of ovarian malignancy algorithm (ROMA), Copenhagen Index (CPH-I) in ovarian neoplasms and establish a nomogram to improve the preoperative evaluation value of ovarian neoplasms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 3,042 patients with ovarian neoplasms were retrospectively classified according to postoperative pathological diagnosis [benign, <jats:italic>n<\/jats:italic>\u2009=\u20092389; epithelial ovarian cancer (EOC), <jats:italic>n<\/jats:italic>\u2009=\u2009653]. The patients were randomly divided into training and test cohorts at a ratio of 7:3. Using CA125, HE4, ROMA, and CPH-I, Receiver operating characteristic (ROC) curves corresponding to different truncation values were calculated and compared, and optimal truncation values were selected. Clinical and imaging risk factors were calculated using univariate regression, and significant variables were selected for multivariate regression analysis combined with ROMA and CPH-I. Nomograms were constructed to predict the occurrence of EOC, and the accuracy was assessed by external validation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>When the cutoff value of CA125, HE4, ROMA, and CPH-I was 100\u2005U\/ml, 70\u2005pmol\/L, 12.5\/14.4% (premenopausal\/postmenopausal) and 5%, respectively, the AUC was 0.674, 0.721, 0.750 and 0.769, respectively. From univariate regression, the clinical risk factors were older age, menopausal status, higher birth rate, hypertension, and diabetes; imaging risk factors were multilocular tumors, solid nodules, bilateral tumors, larger tumor diameter, and ascites. The AUC of the nomogram containing ROMA and CPH-I was 0.8914 and 0.9114, respectively, which was better than the prediction accuracies of CA125, HE4, ROMA, and CPH-I alone. The nomogram with CPH-I was significantly better than that with ROMA (<jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.001), and a nomogram decision curve analysis (DCA) containing CPH-I seemed to have better clinical benefits than ROMA. For external validation of this nomogram containing ROMA and CPH-I, the C-indices were 0.889 and 0.900, and the calibration curves were close to 45\u00b0, showing good agreement with the predicted values.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We conclude that CPH-I and ROMA have higher diagnostic values in the preoperative diagnosis of EOC than other single tumor markers like CA125 or HE4. A nomogram based on CPH-I and ROMA with clinical and ultrasonic indicators had a better diagnostic value, and the CPH-I nomogram had the highest diagnostic efficacy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fsurg.2022.1068492","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T04:56:26Z","timestamp":1673585786000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Copenhagen index (CPH-I) is more favorable than CA125, HE4, and risk\u00a0of ovarian malignancy algorithm (ROMA): Nomogram prediction models with clinical-ultrasonographic feature for diagnosing ovarian neoplasms"],"prefix":"10.3389","volume":"9","author":[{"given":"Zixuan","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00262-020-02544-5","article-title":"Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade","volume":"69","author":"Natoli","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ygyno.2022.04.001","article-title":"Lifetime ovulations and epithelial ovarian cancer risk and survival: a systematic review and meta-analysis","volume":"165","author":"Fu","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"228.e221","DOI":"10.1016\/j.ajog.2010.03.043","article-title":"Comparison of a novel multiple marker assay vs the risk of malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass","volume":"203","author":"Moore","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ygyno.2009.09.041","article-title":"Current state of biomarker development for clinical application in epithelial ovarian cancer","volume":"116","author":"Moore","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.3390\/cancers12123730","article-title":"CA125 and ovarian cancer: a comprehensive review","volume":"12","author":"Charkhchi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1001\/jama.2017.21421","article-title":"Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services task force","volume":"319","author":"Henderson","year":"2018","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1158\/1940-6207.CAPR-11-0378","article-title":"Personalizing CA125 levels for ovarian cancer screening","volume":"4","author":"Dorigo","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/14737140.2017.1360138","article-title":"The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review","volume":"17","author":"Scaletta","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ygyno.2005.06.040","article-title":"Potential markers that complement expression of CA125 in epithelial ovarian cancer","volume":"99","author":"Rosen","year":"2005","journal-title":"Gynecol Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1586\/erm.09.39","article-title":"HE4 As a biomarker for ovarian and endometrial cancer management","volume":"9","author":"Li","year":"2009","journal-title":"Expert Rev Mol Diagn"},{"key":"B14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.gofs.2020.01.015","article-title":"Borderline ovarian tumours: CNGOF guidelines for clinical practice\u2014value of tumor markers","volume":"48","author":"Nyangoh-Timoh","year":"2020","journal-title":"Gynecol Obstet Fertil Senol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","article-title":"Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts","volume":"100","author":"Huhtinen","year":"2009","journal-title":"Br J Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"Galgano","year":"2006","journal-title":"Mod Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000211","article-title":"Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients","author":"Plotti","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.21037\/gs-20-544","article-title":"Role of biomarkers for early detection of ovarian cancer recurrence","volume":"9","author":"Giampaolino","year":"2020","journal-title":"Gland Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1097\/CM9.0000000000000785","article-title":"Age and menopausal status are important factors influencing the serum human epididymis secretory protein 4 level: a prospective cross-sectional study in healthy Chinese people","volume":"133","author":"Cheng","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.3390\/jcm11071994","article-title":"New analytical approach for the alignment of different HE4 automated immunometric systems: an Italian multicentric study","volume":"11","author":"Angeloni","year":"2022","journal-title":"J Clin Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e22624","DOI":"10.1002\/jcla.22624","article-title":"Diagnostic performance of CA 125, HE4, and risk of ovarian malignancy algorithm for ovarian cancer","volume":"33","author":"Kim","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.2147\/CMAR.S199400","article-title":"Clinical value of ROMA index in diagnosis of ovarian cancer: meta-analysis","volume":"11","author":"Cui","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13048-019-0503-7","article-title":"Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review","volume":"12","author":"Dochez","year":"2019","journal-title":"J Ovarian Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ygyno.2015.06.021","article-title":"A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer\u2014an international multicenter study in women with an ovarian mass","volume":"138","author":"Karlsen","year":"2015","journal-title":"Gynecol Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6241743","DOI":"10.1155\/2019\/6241743","article-title":"CPH-I and HE4 are more favorable than CA125 in differentiating borderline ovarian tumors from epithelial ovarian cancer at early stages","volume":"2019","author":"Wang","year":"2019","journal-title":"Dis Markers"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.12122\/j.issn.1673-4254.2019.12.02","article-title":"Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass","volume":"39","author":"Shipeng","year":"2019","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"B28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ygyno.2016.01.023","article-title":"Comparing the Copenhagen index (CPH-I) and risk of ovarian malignancy algorithm (ROMA): two equivalent ways to differentiate malignant from benign ovarian tumors before surgery?","volume":"140","author":"Yoshida","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","article-title":"How to build and interpret a nomogram for cancer prognosis","volume":"26","author":"Iasonos","year":"2008","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1097\/IGC.0000000000000804","article-title":"Diagnostic performance of risk of ovarian malignancy algorithm against CA125 and HE4 in connection with ovarian cancer: a meta-analysis","volume":"26","author":"Dayyani","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ijgo.12371","article-title":"Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors","volume":"140","author":"Minar","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"07TR01","DOI":"10.1088\/1361-6560\/aab4b1","article-title":"Receiver operating characteristic (ROC) curves: review of methods with applications in diagnostic medicine","volume":"63","author":"Obuchowski","year":"2018","journal-title":"Phys Med Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41512-019-0064-7","article-title":"A simple, step-by-step guide to interpreting decision curve analysis","volume":"3","author":"Vickers","year":"2019","journal-title":"Diagn Progn Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/978-3-030-34025-4_18","article-title":"Ovarian cancer biomarkers: moving forward in early detection","volume":"1219","author":"Bonif\u00e1cio","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/978-94-017-7215-0_14","article-title":"The role of CA 125 as tumor marker: biochemical and clinical aspects","volume":"867","author":"Bottoni","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.clinbiochem.2011.04.011","article-title":"Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases","volume":"44","author":"Park","year":"2011","journal-title":"Clin Biochem"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1515\/cclm-2012-0097","article-title":"Human epididymis protein 4 (HE4) in benign and malignant diseases","volume":"50","author":"Hertlein","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","article-title":"Ovarian carcinoma subtypes are different diseases: implications for biomarker studies","volume":"5","author":"K\u00f6bel","year":"2008","journal-title":"PLoS Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.hoc.2018.07.003","article-title":"Early detection of ovarian cancer","volume":"32","author":"Elias","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"B40","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","article-title":"A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer","volume":"97","author":"Jacobs","year":"1990","journal-title":"Br J Obstet Gynaecol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.7314\/APJCP.2016.17.4.2177","article-title":"Predictive value of malignancy risk indices for ovarian masses in premenopausal and postmenopausal women","volume":"17","author":"Ertas","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"B42","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1471-0528.1996.tb09882.x","article-title":"Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses","volume":"103","author":"Tingulstad","year":"1996","journal-title":"Br J Obstet Gynaecol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/00006250-199903000-00028","article-title":"The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals","volume":"93","author":"Tingulstad","year":"1999","journal-title":"Obstet Gynecol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejogrb.2009.02.048","article-title":"Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses","volume":"144","author":"Yamamoto","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3969\/j.issn.1672-8467.2012.04.009","article-title":"Diagnostic value of CA125, ultrasonography and risk of malignancy index (RMI) in postmenopausal ovarian masses","volume":"39","author":"Liang","year":"2012","journal-title":"Fudan Univ J Med Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/uog.5365","article-title":"Simple ultrasound-based rules for the diagnosis of ovarian cancer","volume":"31","author":"Timmerman","year":"2008","journal-title":"Ultrasound Obstet Gynecol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ygyno.2013.04.003","article-title":"A multicenter prospective external validation of the diagnostic performance of IOTA simple descriptors and rules to characterize ovarian masses","volume":"130","author":"Sayasneh","year":"2013","journal-title":"Gynecol Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"c6839","DOI":"10.1136\/bmj.c6839","article-title":"Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group","volume":"341","author":"Timmerman","year":"2010","journal-title":"Br Med J"},{"key":"B49","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ygyno.2016.03.019","article-title":"Rajavithi-ovarian cancer predictive score (R-OPS): a new scoring system for predicting ovarian malignancy in women presenting with a pelvic mass","volume":"141","author":"Yanaranop","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cca.2019.10.002","article-title":"Diagnostic performance of HE4 and ROMA among Chinese women","volume":"500","author":"Shen","year":"2020","journal-title":"Clin Chim Acta"},{"key":"B51","doi-asserted-by":"publisher","first-page":"8762","DOI":"10.3390\/ijms21228762","article-title":"Role of extracellular vesicles in epithelial ovarian cancer: a systematic review","volume":"21","author":"Lucidi","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.1068492\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T04:56:29Z","timestamp":1673585789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.1068492\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":51,"alternative-id":["10.3389\/fsurg.2022.1068492"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2022.1068492","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"article-number":"1068492"}}